

<b>DATE:</b>	15 April 2024
<b>TO:</b>	All Pathologists and Hematologists/Oncologists
<b>FROM:</b>	Molecular Pathology, Alberta Precision Laboratories
<b>RE:</b>	<b>NGS Testing Delays Resolved</b>

---

## PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

---

### Key Message

- The Molecular Pathology South Sector laboratory has resolved the instrument failure affecting Next-Generation Sequencing (NGS) capabilities. The instrument is back online and testing has resumed. During this downtime, testing has been completed via the sendout strategies listed in the prior bulletin.

### Background

- As per the laboratory bulletin distributed on March 20, 2024, an instrument failure affecting NGS capabilities in the Molecular Pathology South laboratory resulted in test requests being triaged and appropriate alternative testing pathways applied. This instrument failure affected the Pan-Solid Tumor Fusion Panel and Lung RNA Fusion Panel (Kinase Fusion Panel) are custom panels designed to cover a broad range of test indications.
- The vendor has provided a resolution to the instrument failure which has been implemented.
- The Molecular Pathology laboratory has completed due diligence verification of the resolution and the instrument has resumed service.

### How this will impact you

- In-house testing is now resumed for all affected NGS panels. Samples received during the downtime have been reported and any backlog specimens have been completed.

### Action Required

- **Pathologists and Oncologists:** Please continue to submit requests in the same way.

**Effective**      **09-Apr-2024**

### Questions/Concerns

- Dr. Adrian Box, Medical/Scientific Director, Molecular Pathology [Adrian.box@albertaprecisionlabs.ca](mailto:Adrian.box@albertaprecisionlabs.ca)
- Dr. Cheryl Mather, Medical Lead, Molecular Pathology North [cheryl.mather@albertaprecisionlabs.ca](mailto:cheryl.mather@albertaprecisionlabs.ca)

### Approved by

- Dr. Adrian Box, Medical/Scientific Director, Molecular Pathology Program
- Mark Douesnard, Operations Director, Molecular Pathology Program
- Dr. Carolyn O'Hara, Chief Medical Laboratory Officer (Interim), Alberta Precision Laboratories

*Effective September 1, 2023, APL has become the sole provider of all public lab services in Alberta. As a result, community lab services formally provided by DynaLIFE Medical Labs will become the responsibility of Alberta Precision Labs (APL). This change impacts all zones.*